{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T05:24:45Z","timestamp":1761110685474,"version":"3.44.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpharmsci.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Pharmaceutical Sciences"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.xphs.2023.10.025","type":"journal-article","created":{"date-parts":[[2023,10,21]],"date-time":"2023-10-21T10:56:25Z","timestamp":1697885785000},"page":"167-175","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Target Reserve and Turnover Parameters Determine Rightward Shift of Enalaprilat Potency From its Binding Affinity to the Angiotensin Converting Enzyme"],"prefix":"10.1016","volume":"113","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1996-9340","authenticated-orcid":false,"given":"Van Anh","family":"Nguyen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Li","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leonid","family":"Kagan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Malcolm","family":"Rowland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4848-0440","authenticated-orcid":false,"given":"Donald E.","family":"Mager","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.xphs.2023.10.025_bib0001","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1146\/annurev.pharmtox.47.120505.105154","article-title":"Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis","volume":"47","author":"Danhof","year":"2007","journal-title":"Annu Rev Pharmacol Toxicol"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.025_bib0002","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1016\/S0022-3565(25)22414-4","article-title":"Target-based warfarin pharmacokinetics in the rat: the link with the anticoagulant effect","volume":"270","author":"Thijssen","year":"1994","journal-title":"J Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0003","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1002\/jps.10345","article-title":"Comparative pharmacokinetics of coumarin anticoagulants L: physiologic modeling of S-warfarin in rats and pharmacologic target-mediated warfarin disposition in man","volume":"92","author":"Levy","year":"2003","journal-title":"J Pharm Sci"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0004","first-page":"605","article-title":"The implications of non-linear red blood cell partitioning for the pharmacokinetics and pharmacodynamics of the nucleoside transport inhibitor draflazine","volume":"42","author":"Snoeck","year":"1996","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.025_bib0005","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1111\/j.1476-5381.1956.tb00006.x","article-title":"A modification of receptor theory","volume":"11","author":"Stephenson","year":"1956","journal-title":"Br J Pharmacol Chemother"},{"issue":"1219","key":"10.1016\/j.xphs.2023.10.025_bib0006","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1098\/rspb.1983.0093","article-title":"Operational models of pharmacological agonism","volume":"220","author":"Black","year":"1983","journal-title":"Proc R Soc Lond B"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0007","first-page":"32","article-title":"Affinity and intrinsic activity in the theory of competitive inhibition. I. Problems and theory","volume":"99","author":"Ariens","year":"1954","journal-title":"Arch Int Pharmacodyn Ther"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.025_bib0008","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1111\/j.1476-5381.1992.tb14322.x","article-title":"Evidence that the apparent complexity of receptor antagonism by angiotensin II analogues is due to a reversible and syntopic action","volume":"106","author":"Liu","year":"1992","journal-title":"Br J Pharmacol"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.025_bib0009","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1111\/j.1365-2885.2004.00601.x","article-title":"Pharmacokinetics and pharmacokinetic\/pharmacodynamic relationships for angiotensin-converting enzyme inhibitors","volume":"27","author":"Toutain","year":"2004","journal-title":"J Vet Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.025_bib0010","doi-asserted-by":"crossref","first-page":"274","DOI":"10.2165\/00003088-199325040-00003","article-title":"Enalapril clinical pharmacokinetics and pharmacokinetic-pharmacodynamic relationships. An overview","volume":"25","author":"MacFadyen","year":"1993","journal-title":"Clin Pharmacokinet"},{"issue":"Suppl 2","key":"10.1016\/j.xphs.2023.10.025_bib0011","first-page":"215S","article-title":"An overview of the clinical pharmacology of enalapril","volume":"18","author":"Davies","year":"1984","journal-title":"Br J Clin Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.025_bib0012","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1002\/bdd.2510050309","article-title":"Pharmacokinetics of repeated single oral doses of enalapril maleate (MK-421) in normal volunteers","volume":"5","author":"Till","year":"1984","journal-title":"Biopharm Drug Dispos"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0013","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1097\/00005344-198701000-00006","article-title":"Pharmacokinetics of the converting enzyme inhibitor cilazapril in normal volunteers and the relationship to enzyme inhibition: development of a mathematical model","volume":"9","author":"Francis","year":"1987","journal-title":"J Cardiovasc Pharmacol"},{"issue":"7","key":"10.1016\/j.xphs.2023.10.025_bib0014","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1002\/bdd.368","article-title":"Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers","volume":"24","author":"Najib","year":"2003","journal-title":"Biopharm Drug Dispos"},{"year":"2019","series-title":"PinPoint Digitizer","author":"Ismail","key":"10.1016\/j.xphs.2023.10.025_bib0015"},{"key":"10.1016\/j.xphs.2023.10.025_bib0016","doi-asserted-by":"crossref","first-page":"1709","DOI":"10.2147\/DDDT.S65678","article-title":"Multiple-dose pharmacokinetics and pharmacodynamics of evogliptin (DA-1229), a novel dipeptidyl peptidase IV inhibitor, in healthy volunteers","volume":"8","author":"Gu","year":"2014","journal-title":"Drug Des Devel Ther"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0017","doi-asserted-by":"crossref","first-page":"E1","DOI":"10.1161\/hy0102.102293","article-title":"Angiotensin II suppression in humans by the orally active renin inhibitor Aliskiren (SPP100): comparison with enalapril","volume":"39","author":"Nussberger","year":"2002","journal-title":"Hypertension"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0018","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1097\/00005344-200405000-00018","article-title":"Gender differences in angiotensin-converting enzyme (ACE) activity and inhibition by enalaprilat in healthy volunteers","volume":"43","author":"Zapater","year":"2004","journal-title":"J Cardiovasc Pharmacol"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0019","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1007\/BF01071348","article-title":"Pharmacokinetics of an ACE inhibitor, S-9780, in man: evidence of tissue binding","volume":"17","author":"Lees","year":"1989","journal-title":"J Pharmacokinet Biopharm"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0020","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1007\/s10928-012-9267-z","article-title":"Methods of solving rapid binding target-mediated drug disposition model for two drugs competing for the same receptor","volume":"39","author":"Yan","year":"2012","journal-title":"J Pharmacokinet Pharmacodyn"},{"year":"1985","series-title":"Vasotec: Biopharmaceutics NDA Review","key":"10.1016\/j.xphs.2023.10.025_bib0021"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0022","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/sj.clpt.6100495","article-title":"Pharmacokinetic\/pharmacodynamic modeling of renin biomarkers in subjects treated with the renin inhibitor aliskiren","volume":"84","author":"Hong","year":"2008","journal-title":"Clin Pharmacol Ther"},{"year":"2009","series-title":"ADAPT 5 User's Guide: Pharmacokinetic\/Pharmacodynamic Systems Analysis Software","author":"D'Argenio","key":"10.1016\/j.xphs.2023.10.025_bib0023"},{"issue":"9","key":"10.1016\/j.xphs.2023.10.025_bib0024","doi-asserted-by":"crossref","first-page":"1729","DOI":"10.1016\/0006-2952(91)90509-4","article-title":"The role of enzyme and substrate concentration in the evaluation of serum angiotensin converting enzyme (ACE) inhibition by enalaprilat in vitro","volume":"42","author":"Weisser","year":"1991","journal-title":"Biochem Pharmacol"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.025_bib0025","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/S0022-3565(24)35393-5","article-title":"Benazeprilat disposition and effect in dogs revisited with a pharmacokinetic\/pharmacodynamic modeling approach","volume":"292","author":"Toutain","year":"2000","journal-title":"J Pharmacol Exp Ther"},{"issue":"7","key":"10.1016\/j.xphs.2023.10.025_bib0026","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1042\/BCJ20200060","article-title":"ACE-domain selectivity extends beyond direct interacting residues at the active site","volume":"477","author":"Cozier","year":"2020","journal-title":"Biochem J"},{"issue":"14","key":"10.1016\/j.xphs.2023.10.025_bib0027","doi-asserted-by":"crossref","first-page":"9002","DOI":"10.1016\/S0021-9258(18)31543-6","article-title":"The two homologous domains of human angiotensin I-converting enzyme are both catalytically active","volume":"266","author":"Wei","year":"1991","journal-title":"J Biol Chem"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0028","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0005-2736(95)00030-7","article-title":"Molecular mechanism for the relative binding affinity to the intestinal peptide carrier. Comparison of three ACE-inhibitors: enalapril, enalaprilat, and lisinopril","volume":"1236","author":"Swaan","year":"1995","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.xphs.2023.10.025_bib0029","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.pharmthera.2017.10.011","article-title":"In vivo potency revisited - keep the target in sight","volume":"184","author":"Gabrielsson","year":"2018","journal-title":"Pharmacol Ther"},{"issue":"8","key":"10.1016\/j.xphs.2023.10.025_bib0030","doi-asserted-by":"crossref","first-page":"1273","DOI":"10.1016\/0006-2952(84)90180-1","article-title":"Kinetics of inhibition of angiotensin converting enzyme by captopril and by enalapril diacid","volume":"33","author":"Reynolds","year":"1984","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.xphs.2023.10.025_bib44","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1007\/s10928-020-09734-9","article-title":"Estimating drug potency in the competitive target mediated drug disposition (TMDD) system when the endogenous ligand is included","volume":"48","author":"Alaybeyoglu","year":"1989","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"Pt 2","key":"10.1016\/j.xphs.2023.10.025_bib0031","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/000456328902600224","article-title":"Intra- and inter-individual variation of serum angiotensin converting enzyme: clinical implications","volume":"26","author":"Fogarty","year":"1989","journal-title":"Ann Clin Biochem"},{"issue":"6396","key":"10.1016\/j.xphs.2023.10.025_bib0032","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1038\/359641a0","article-title":"Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction","volume":"359","author":"Cambien","year":"1992","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0033","first-page":"197","article-title":"Evidence, from combined segregation and linkage analysis, that a variant of the angiotensin I-converting enzyme (ACE) gene controls plasma ACE levels","volume":"51","author":"Tiret","year":"1992","journal-title":"Am J Hum Genet"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.025_bib0034","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1006\/bbrc.1993.1231","article-title":"Association analysis of a polymorphism of the angiotensin converting enzyme gene with essential hypertension in the Japanese population","volume":"191","author":"Higashimori","year":"1993","journal-title":"Biochem Biophys Res Commun"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.025_bib0035","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1038\/clpt.1994.134","article-title":"Pharmacologic target-mediated drug disposition","volume":"56","author":"Levy","year":"1994","journal-title":"Clin Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.xphs.2023.10.025_bib0036","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1023\/A:1014414520282","article-title":"General pharmacokinetic model for drugs exhibiting target-mediated drug disposition","volume":"28","author":"Mager","year":"2001","journal-title":"J Pharmacokinet Pharmacodyn"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.025_bib0037","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/BF01061691","article-title":"Comparison of four basic models of indirect pharmacodynamic responses","volume":"21","author":"Dayneka","year":"1993","journal-title":"J Pharmacokinet Biopharm"},{"issue":"3","key":"10.1016\/j.xphs.2023.10.025_bib0038","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1046\/j.1365-2125.1998.00676.x","article-title":"Characteristics of indirect pharmacodynamic models and applications to clinical drug responses","volume":"45","author":"Sharma","year":"1998","journal-title":"Br J Clin Pharmacol"},{"issue":"1","key":"10.1016\/j.xphs.2023.10.025_bib0039","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1081\/CBI-100101034","article-title":"Algorithm for application of Fourier analysis for biorhythmic baselines of pharmacodynamic indirect response models","volume":"17","author":"Krzyzanski","year":"2000","journal-title":"Chronobiol Int"},{"issue":"4","key":"10.1016\/j.xphs.2023.10.025_bib0040","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/clpt.1993.167","article-title":"Gender-based effects on methylprednisolone pharmacokinetics and pharmacodynamics","volume":"54","author":"Lew","year":"1993","journal-title":"Clin Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.xphs.2023.10.025_bib0041","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1124\/dmd.31.5.510","article-title":"Diversity of mechanism-based pharmacodynamic models","volume":"31","author":"Mager","year":"2003","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"10.1016\/j.xphs.2023.10.025_bib0042","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1124\/pr.119.018101","article-title":"Transitioning from basic toward systems pharmacodynamic models: lessons from corticosteroids","volume":"72","author":"Ayyar","year":"2020","journal-title":"Pharmacol Rev"},{"issue":"9","key":"10.1016\/j.xphs.2023.10.025_bib0043","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1002\/jps.23590","article-title":"Moving from basic toward systems pharmacodynamic models","volume":"102","author":"Jusko","year":"2013","journal-title":"J Pharm Sci"}],"container-title":["Journal of Pharmaceutical Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004331?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022354923004331?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,20]],"date-time":"2025-09-20T09:46:21Z","timestamp":1758361581000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022354923004331"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":44,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024,1]]}},"alternative-id":["S0022354923004331"],"URL":"https:\/\/doi.org\/10.1016\/j.xphs.2023.10.025","relation":{},"ISSN":["0022-3549"],"issn-type":[{"type":"print","value":"0022-3549"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Target Reserve and Turnover Parameters Determine Rightward Shift of Enalaprilat Potency From its Binding Affinity to the Angiotensin Converting Enzyme","name":"articletitle","label":"Article Title"},{"value":"Journal of Pharmaceutical Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.xphs.2023.10.025","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 American Pharmacists Association. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}